Gepirone

Gepirone is a selective serotonin 5-HT1A receptor agonist and certified reference standard developed for the treatment of major depressive disorder. As the active pharmaceutical ingredient developed under the code name Alnespirone, Gepirone has demonstrated potential in clinical trials for the treatment of depression. In pharmaceutical quality control contexts, Gepirone serves as the primary reference standard for impurity profiling, analytical method development, and regulatory submissions. Gepirone is recognized through multiple regulatory designations, making it indispensable for quality control testing. The drug substance Gepirone exhibits excellent stability when stored under recommended conditions. Furthermore, Gepirone functions through a distinct mechanism from traditional antidepressants, demonstrating the therapeutic potential of this well-characterized molecular scaffold in psychiatric medicine.

Product Parameters

Synthetic Route

 Mechanism Of Action

Gepirone specifically activates the 5-HT1A receptor, modulates serotoninergic neurotransmission in the prefrontal cortex and limbic system, and improves emotional regulation; compared with traditional selective serotonin reuptake inhibitors (SSRIs), it may reduce side effects such as sexual dysfunction.

R&D History

After Bristol-Myers Squibb granted the development rights to Fabre-Kramer in 1993, the company collaborated with both Organon and GlaxoSmithKline (GSK), but neither partnership secured regulatory approval. Ultimately, Fabre-Kramer independently completed its Phase III clinical trials and successfully obtained approval, becoming the world's first approved 5-HT1A-targeted antidepressant and offering a novel, differentiated approach to monoamine system modulation for the treatment of depression.

Contact Us

Partner with Cosperpharm for Gepirone that delivers the purity, documentation, and supply reliability your research program requires.